Latest Conference Articles

Rapport Therapeutics' RAP-219 achieved seizure freedom in 24% of patients with drug-resistant focal epilepsy over 8 weeks in a phase 2 trial.

A cognitive neurologist outlines the current Alzheimer disease treatment landscape.

How community oncology practices are expanding access to innovative therapies while navigating reimbursement and care delivery challenges.

AI is delivering immediate clinical value in neurology—from ambient scribes and clinical decision support to trial recruitment and medical education.

A Harvard population health researcher presents findings linking adolescent food insecurity to a cluster of brain health risk factors.

Ecopipam reduces Tourette tic relapse risk by approximately 50% with durable control and no movement-related adverse effects.

AACR data show tumor molecular profiling finds actionable PIK3CA in breast and colorectal cancer, while ctDNA adds real-time monitoring in oncology.

Phase 3 data show quarterly cemdisiran injections improve gMG symptoms, either and matches or outperforms all study end points compared to combination therapy.

Bocunebart, a novel anti-PACAP antibody, targets a distinct neurological pathway from existing CGRP therapies.

Phase 3 METEOROID shows IL-6 blocker satralizumab cuts MOGAD relapses 68%, with rapid onset and placebo-like safety.

Cemdisiran’s RNA-targeting mechanism is a compelling new option in the generalized myasthenia gravis treatment landscape.

The research highlights the influence of hormonal changes on treatment selection and the need for more tailored, life stage–specific care.

The data, which were presented at the AAN 2026 Annual Meeting, support the agents’ neurological safety, but longer follow-ups and dedicated outcome trials are needed to confirm these findings.

Phase 3 SYMPHONY clinical trial data show reboxetine eases narcolepsy type 1 symptoms, improving functional impairment due to excessive daytime sleepiness (EDS) as well as mood symptoms.

Biological sex and societal gender factors independently—and differently—influence TBI mortality, discharge destination, and long-term cognitive recovery.

Despite the availability of 4 FDA-approved biologics, the majority of NMOSD patients remain on off-label rituximab.

The menopausal transition alters brain circuitry and estrogen signaling in ways that may elevate risk for Alzheimer disease.

Sex and gender differences remain critically underrepresented in traumatic brain injury clinical guidelines.

Real-world data show pharmacist-driven obesity care models may offer greater improvements in hemoglobin A1C and lipid parameters while supporting multidisciplinary, patient-centered care.

PCOS in female athletes often goes unrecognized due to atypical presentations, requiring careful differentiation, individualized management, and a multidisciplinary approach to protect both performance and long-term health.

Insights on the growth of sports pharmacy and the increasing demand for pharmacist expertise in athlete care.

There is a growing need to integrate pharmacists into sports medicine teams, where their expertise in medication safety, chronic disease management, and supplements can significantly enhance athlete care and performance.

This interview highlights the importance of integrating holistic health, lifestyle coaching, and medication management to create more effective, patient-centered care.

Pharmacists play a critical role in bridging athlete performance and safety, emphasizing foundational health habits, addressing supplement misconceptions, and supporting mental health through frequent, trusted patient interactions.